The Russell reconstitution impact on the INSM share price is a blip compared to the fundamental challenges faced by the company.
It is interesting to note that ArikayceRocks and Terry (bitter INSM Msg Board rivals) share the same faith in the trading value of the Russell event. I prefer facts - Visium is liquidating its INSM holdings at a steep loss. A few days will bring clarity.
Visium is back in the news today. This fund bought a bunch of INSM shares in Q1 2016. They need to liquidate their 1.5 million shares. That should put more downward pressure on INSM share price. An institution charged with fraud in BioTech who also recently invested in INSM is a dark cloud for longs.
The legal challenges after the EMEA withdrawal are a further risk factor. The silence from management extends doubt.
INSM does have about $4/share in cash. That should be a point of stability. However, INSM has a history of trading below cash value during the Iplex for ALS days.
Sorry no results. The article specifies the problems and extra cost of current VEGF therapy versus the Smith/Hellstrom/Lofqvist model of ROP. The PremiCure group also had a recent advocacy article in favor of PremIplex.
INSM should be proud that they helped to initiate this therapy. The fact that the SHIRE study completed all four sections A, B, C, and D of its Phase II study is an indication that the therapy is beneficial. Otherwise, the later sections would have been canceled. The results for over 120 premature infants exist; just not released yet. My guess is that it will take several months. Thank you INSM. And, thanks to SHIRE.
"Biological agents that are currently being studied include IGF-1 with IGF-binding protein-3 (rhIGF-1 + rhIGFBP-3) and propranolol."
"Understanding the two phases of ROP will help to identify appropriate therapeutic strategies and improve visual outcomes in many preterm infants globally. "
Neonatology. 2016;109(4):369-76. doi: 10.1159/000444901. Epub 2016 Jun 3.